Gene Expression

Quark acquires microarray facility assets

Published in Gene Therapy Weekly, August 22nd, 2002

Quark Biotech, Inc., a privately owned drug discovery company announced the acquisition of Incyte Genomics' microarray facility assets to strengthen its capabilities for high throughput functional screening, target validation, and chemical screening to accelerate drug development.

Financial terms were not disclosed.

"We are utilizing microarrays for the functional profiling of proteins by identifying key genes and proteins directly related to the clinical endpoint and will be using a 'chemical library chip' to find small molecules interacting with those key proteins," said Daniel Zurr, CEO of Quark Biotech.

"The enhanced...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-08-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry